X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
04 août 2022 07h05 HE
|
X4 Pharmaceuticals
Highlights notable upcoming milestones including data from Phase 1b trial in chronic neutropenia, expected in late September, and results from global, pivotal Phase 3 trial in WHIM syndrome, expected...
X4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022
26 juil. 2022 16h05 HE
|
X4 Pharmaceuticals
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones
20 juil. 2022 16h10 HE
|
X4 Pharmaceuticals
Company now focused on advancing lead clinical candidate mavorixafor in chronic neutropenic disorders, including WHIM syndrome Important mavorixafor clinical milestones anticipated in 2H 2022,...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 juil. 2022 16h30 HE
|
X4 Pharmaceuticals
BOSTON, July 01, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months
30 juin 2022 19h52 HE
|
X4 Pharmaceuticals
BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people...
X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor
16 mai 2022 06h05 HE
|
X4 Pharmaceuticals
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with...
X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
12 mai 2022 06h05 HE
|
X4 Pharmaceuticals
Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome expected in 4Q22 Clinical and regulatory updates from ongoing chronic neutropenia Phase 1b study anticipated during 3Q 2022;...
X4 Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 12, 2022
03 mai 2022 06h05 HE
|
X4 Pharmaceuticals
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mai 2022 16h05 HE
|
X4 Pharmaceuticals
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022
08 avr. 2022 13h05 HE
|
X4 Pharmaceuticals
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people...